Ruxolitinib patent expiry?

What will happen when the ruxolitinib patent expires?

Ruxolitinib, a potent JAK inhibitor, is marketed under the brand name Jakafi by Incyte Corporation for the treatment of myelofibrosis and polycythemia vera [1]. As ruxolitinib's patent approaches expiration, several pharmaceutical companies are already racing to develop biosimilar versions of the drug [2]. Biosimilars are biologic medications that are highly similar to and have no clinically meaningful differences from existing biologics, often at significantly lower prices.

Can biosimilars enter the market before the patent expiry?

The US FDA has been actively streamlining the approval process for biosimilars since the Biologics Price Competition and Innovation Act of 2009. However, biosimilar manufacturers must demonstrate a high degree of similarity in safety and efficacy to approved biologics. While biosimilars cannot be approved until the original biologic's patent expires, it's possible that regulatory agencies may grant provisional marketing permission as early as one year before patent expiry, provided the applicant has shown substantial evidence of biosimilarity during the review process.

How will ruxolitinib's patent expiry impact the market?

The patent expiry of ruxolitinib is expected to have a significant impact on the biologic market. Companies such as Pfizer and Roche are already exploring strategies to maintain market share in the JAK inhibitor segment. Incyte Corporation has been taking steps to strengthen its portfolio with complementary assets, such as the late-stage compound, itacitinib [3].

What is the timeline for ruxolitinib's patent expiry?

The expiration date for the ruxolitinib patent is currently [4] set at the end of (year), with patent extensions possible through [5] patent continuations that extend the life of the patent. Keep in mind, patent expirations can change, and we recommend consulting with a legal or industry expert for the most up-to-date information.

[1] - DrugPatentWatch.com
[2] - [www.drugpatentwatch.com/biosimilars]
[3] - [www.drugpatentwatch.com/itacitinib]
[4] - DrugPatentWatch.com - ruxolitinib patent expiry (year)
[5] - DrugPatentWatch.com - ruxolitinib patent extensions (year)